Deutsche Bank AG Grows Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Deutsche Bank AG lifted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 11.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 822,108 shares of the biopharmaceutical company's stock after acquiring an additional 87,491 shares during the quarter. Deutsche Bank AG owned approximately 0.28% of Amicus Therapeutics worth $7,744,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. HealthInvest Partners AB grew its stake in shares of Amicus Therapeutics by 18.6% during the 4th quarter. HealthInvest Partners AB now owns 326,840 shares of the biopharmaceutical company's stock worth $3,076,000 after acquiring an additional 51,368 shares during the period. Tempus Wealth Planning LLC bought a new position in Amicus Therapeutics in the 4th quarter worth about $259,000. Intech Investment Management LLC boosted its stake in Amicus Therapeutics by 59.7% in the 4th quarter. Intech Investment Management LLC now owns 124,704 shares of the biopharmaceutical company's stock worth $1,175,000 after purchasing an additional 46,633 shares during the period. Norges Bank bought a new position in Amicus Therapeutics in the 4th quarter worth about $29,033,000. Finally, Renaissance Technologies LLC boosted its stake in Amicus Therapeutics by 174.1% in the 4th quarter. Renaissance Technologies LLC now owns 2,108,616 shares of the biopharmaceutical company's stock worth $19,863,000 after purchasing an additional 1,339,316 shares during the period.

Analyst Upgrades and Downgrades

Several research analysts have commented on FOLD shares. The Goldman Sachs Group cut their target price on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. UBS Group raised their target price on Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Wells Fargo & Company cut their target price on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research note on Thursday, February 20th. Wall Street Zen downgraded Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Finally, Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, Amicus Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $16.22.

Amicus Therapeutics Price Performance

Shares of NASDAQ:FOLD traded down $0.04 on Friday, hitting $6.22. The company's stock had a trading volume of 2,822,292 shares, compared to its average volume of 2,841,418. The company has a 50-day simple moving average of $7.11 and a 200 day simple moving average of $8.74. Amicus Therapeutics, Inc. has a 1 year low of $5.81 and a 1 year high of $12.65. The company has a market capitalization of $1.92 billion, a PE ratio of -34.56, a PEG ratio of 1.51 and a beta of 0.64. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.